Promising New Targets for the Treatment of Infections Caused by Acinetobacter baumannii: A Review.

IF 3 4区 医学 Q2 PHARMACOLOGY & PHARMACY Current drug targets Pub Date : 2024-01-01 DOI:10.2174/0113894501319269240819060245
Kellen Christina Malheiros Borges, André Kipnis, Bruno Junior Neves, Ana Paula Junqueira-Kipnis
{"title":"Promising New Targets for the Treatment of Infections Caused by <i>Acinetobacter baumannii</i>: A Review.","authors":"Kellen Christina Malheiros Borges, André Kipnis, Bruno Junior Neves, Ana Paula Junqueira-Kipnis","doi":"10.2174/0113894501319269240819060245","DOIUrl":null,"url":null,"abstract":"<p><p><i>Acinetobacter baumannii</i> is a globally disseminated Gram-negative bacterium that causes several types of serious nosocomial infections, the most worrisome being ventilator-associated pneumonia and bacteremia related to using venous catheters. Due to its great ability to form biofilms, combined with its survival for prolonged periods on abiotic surfaces and its potential to acquire and control the genes that determine antibiotic resistance, <i>A. baumannii</i> is at the top of the World Health Organization's priority list of pathogens in urgent need of new therapies. In this sense, this review aimed to present and discuss new molecular targets present in A. baumannii with potential for promising treatment approaches. This review highlights crucial molecular targets, including cell division proteins, membrane synthesis enzymes, and biofilm-associated components, offering promising targets for novel antimicrobial drug development against <i>A. baumannii</i> infections.</p>","PeriodicalId":10805,"journal":{"name":"Current drug targets","volume":" ","pages":"971-986"},"PeriodicalIF":3.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113894501319269240819060245","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Acinetobacter baumannii is a globally disseminated Gram-negative bacterium that causes several types of serious nosocomial infections, the most worrisome being ventilator-associated pneumonia and bacteremia related to using venous catheters. Due to its great ability to form biofilms, combined with its survival for prolonged periods on abiotic surfaces and its potential to acquire and control the genes that determine antibiotic resistance, A. baumannii is at the top of the World Health Organization's priority list of pathogens in urgent need of new therapies. In this sense, this review aimed to present and discuss new molecular targets present in A. baumannii with potential for promising treatment approaches. This review highlights crucial molecular targets, including cell division proteins, membrane synthesis enzymes, and biofilm-associated components, offering promising targets for novel antimicrobial drug development against A. baumannii infections.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
治疗鲍曼不动杆菌感染的有望新靶点:综述。
鲍曼不动杆菌(Acinetobacter baumannii)是一种全球传播的革兰氏阴性细菌,可引起多种类型的严重院内感染,其中最令人担忧的是呼吸机相关性肺炎和与使用静脉导管有关的菌血症。由于鲍曼不动杆菌具有很强的形成生物膜的能力,而且能在非生物表面长期存活,并有可能获得和控制决定抗生素耐药性的基因,因此鲍曼不动杆菌被世界卫生组织列为急需新疗法的病原体之首。从这个意义上讲,本综述旨在介绍和讨论鲍曼不动杆菌中存在的新分子靶点,这些靶点有可能成为有前景的治疗方法。本综述强调了关键的分子靶点,包括细胞分裂蛋白、膜合成酶和生物膜相关成分,为开发新型抗菌药物治疗鲍曼不动杆菌感染提供了前景广阔的靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current drug targets
Current drug targets 医学-药学
CiteScore
6.20
自引率
0.00%
发文量
127
审稿时长
3-8 weeks
期刊介绍: Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Current Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of drug targets. The journal also accepts for publication mini- & full-length review articles and drug clinical trial studies. As the discovery, identification, characterization and validation of novel human drug targets for drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
期刊最新文献
Unraveling Neurological Drug Delivery: Polymeric Nanocarriers for Enhanced Blood-Brain Barrier Penetration. LncRNA HAGLROS: A Vital Oncogenic Propellant in Various Human Cancers. Trends of Artificial Intelligence (AI) Use in Drug Targets, Discovery and Development: Current Status and Future Perspectives. Current Updates on Pathogenesis, Systemic Therapy, and Treatment of Invasive Fungal Infections. Molecular Insight into Obesity-Associated Nephropathy: Clinical Implications and Possible Strategies for its Management.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1